![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 4 of 4. This is the beginning of the thread.
Posted by SalArmy4me on September 6, 2001, at 2:49:40
The one study that showed Moclobemide to be weaker than clomipramine in depression used a wimpy dose of moclobemide (400 mg). All other evidence points out that moclobemide is very effective in depression--as effective as the tricyclics themselves without tricyclic side-effects.
KRAGH-SORENSEN, PER. Moclobemide Versus Clomipramine in Depressed Patients in General Practice. A Randomized, Double-Blind, Parallel, Multicenter Study. J Clin Psychopharmacology. 15(4S) Aug 95:
"No statistically significant differences in the efficacy of clomipramine and moclobemide were found. Because no statistically significant differences were found in outcome between the two diagnostic groups (endogenous and nonendogenous), Table 5 and Table 6 show the combined results for the two diagnostic groups. The results of the global rating with CGAS and CGAE were uniform: there were no significant differences in therapeutic effect between moclobemide and clomipramine..."
ANGST, JULES. Moclobemide and Tricyclic Antidepressants in Severe Depression: Meta-Analysis and Prospective Studies. Journal of Clinical Psychopharmacology. 15(4S) Supplement 2:16S- Aug 95:
"The comparison of imipramine, another standard antidepressant, with moclobemide did not show any significant differences in efficacy. Here, the majority of studies were done relatively late in the development of moclobemide and therefore with moclobemide doses corresponding to the established 3:1 moclobemide:TCA ratio (moclobemide, 453 mg/day; imipramine, 159 mg/day)."
Beaumont G. A randomised, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice. Int Clin Psychopharmacol. 1993;7:159-165:
"Both treatments resulted in significant improvement; this was greater in the dothiepin-treated group and the difference was statistically significant, although clinically small."
Casacchia, M. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry 7, 122-125:
"Marked improvement was observed by the CGI in 15 cases treated with Moclobemide and mild to moderate in 5 cases who received placebo. The treatment was well tolerated."
Posted by SLS on September 6, 2001, at 8:16:45
In reply to Moclobemide: Weak?, posted by SalArmy4me on September 6, 2001, at 2:49:40
Dear Sal,
Moclobemide pretty much well sucks.
As far as double blind etc. studies are concerned, every antidepressant ever tested seems to be as effective as the reference drugs imipramine or fluoxetine. This is, of course, not true.
It is often difficult to glean from medical literature what is accurate and what is not. It takes a good bit of reading, listening, and viewing. It also takes enough of an education, whatever that may be, to reasonably consider the information appropriated by this research.
Many of the papers you'll find on Medline and appearing in peer-reviewed journals are simply reviews of the literature, sometimes using Medline as the source of its information. In other words, it takes experts to review the work of other experts (and non-experts). These Ph.D.s and M.D.s devote more than just a few minutes cutting-and-pasting stuff found on the Internet.
Moclobemide pretty much well sucks.
That being said, I am sure there are plenty of people in the world for whom it is a miracle drug, and I would never want to see moclobemide withdrawn from the market. It has its place.
- Scott
Posted by SalArmy4me on September 6, 2001, at 8:39:13
In reply to Re: Moclobemide: Weak? » SalArmy4me, posted by SLS on September 6, 2001, at 8:16:45
Show me evidence that moclobemide has little efficacy and I might believe you. But all the evidence points to the contrary. After all, moclobemide is as effective as Clomipramine, the most widely used antidepressant in Europe--and the most successful in inpatients worldwide.
Posted by JahL on September 6, 2001, at 8:47:22
In reply to Re: Moclobemide: Weak? » SLS, posted by SalArmy4me on September 6, 2001, at 8:39:13
> Show me evidence that moclobemide has little efficacy and I might believe you. But all the evidence points to the contrary. After all, moclobemide is as effective as Clomipramine, the most widely used antidepressant in Europe--and the most successful in inpatients worldwide.
I've never met a pdoc with a good word to say about it. Clomipramine OTOH is highly regarded over here.
J.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.